Drug intelligence / Profile preview

Vectra VAG

Development stage
Unknown
Lead developer
Thoratec
Modality
Small Molecules
Administration
Implant
01

Overview

Vectra VAG is a veterinary pharmaceutical product, specifically a topical ectoparasiticide formulation developed for the control and prevention of flea and tick infestations in dogs. It typically contains a combination of active ingredients such as dinotefuran, pyriproxyfen, and permethrin. Dinotefuran acts as a fast-acting insecticide by binding to the nicotinic acetylcholine receptors in the insect's nervous system, leading to paralysis and death. Pyriproxyfen is an insect growth regulator (IGR) that mimics juvenile hormone, preventing the development of flea eggs and larvae into adults. Permethrin provides repellent and insecticidal activity against ticks, mosquitoes, and biting flies by disrupting sodium channel kinetics in their nerve cells. The 'VAG' designation is often associated with specific regional branding or packaging variations of the Vectra 3D line produced by Ceva Santé Animale.

Brand names
Vectra VAG
Other names
dinotefuran + pyriproxyfen + permethrin
02

Targets

NaV (Voltage-gated sodium channels)Nicotinic Acetylcholine ReceptorMET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on Vectra VAG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vectra VAG.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call